UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). Issue 5 (8th September 2019)

• Record Type: Journal Article
• Authors: Vaz-Luis, Ines; Cottu, Paul; Mesleard, Christel; Martin, Anne Laure; Dumas, Agnes; Dauchy, Sarah; Tredan, Olivier; Levy, Christelle; Adnet, Johan; Rousseau Tsangaris, Marina; Andre, Fabrice; Arveux, Patrick
• Is Part Of: ESMO open. Volume 4:Issue 5(2019)
• Publication Date: 2019-09-08
• Subjects: cohort study -- breast cancer -- survivorship -- toxicity -- quality of life; Cancer -- Periodicals; 616.994005
• DOI: 10.1136/esmoopen-2019-000562
• Languages: English
• ISSNs: 2059-7029

Abstract

Abstract : Background: Corresponding with improved survival among patients with breast cancer, the awareness of the long-term effects of cancer treatments has increased. CANcer TOxicities (CANTO) aims to identify predictors of development and persistence of long-term toxicities in patients treated for stages I–III breast cancer and to characterise their incidence, as well their impact. In this paper, we describe the methodology used in this study and provide a first characterisation of the study population. Methods: CANTO (NCT01993498 ) is a French prospective, longitudinal cohort study enrolling patients with invasive cT0-cT3cN0-3M0 breast cancer of 26 French cancer centres. Patients are assessed at diagnosis, 3–6 (M0), 12 (M12), 36 (M36) and 60 (M60) months after completion of primary surgery, chemotherapy or radiotherapy whichever comes last. CANTO collects clinical, treatment, toxicity data, an extensive list of validated patient-reported outcomes (focusing on quality of life, psychological and behavioural questionnaires) and ad hoc socioeconomic questionnaires. Blood collection is performed at diagnosis, M0, M12, M36 and M60. Biologic sub-studies are ongoing (eg, microbiotic and cognitive sub-study). Results: Enrolment started in 2012; by October 2018, 12 012 patients had been enrolled. Data collected have a low missing completion rate (<5% for key clinical variables, <20% for patient-reported outcomes). Blood, serum and plasma samples are stored in over 96% of patients. Among the first 5801 patients enrolled in CANTO, 76.7% of patients had hormone receptor positive and human epidermal growth factor 2 negative tumours; 73.1% of patients had breast conserving surgery; 90.4% received adjuvant radiotherapy, 53.4% (neo) adjuvant chemotherapy, 11.3% adjuvant trastuzumab and 80.3% adjuvant hormonotherapy. Conclusions: CANTO represents a unique opportunity to explore important medical, biological and psychosocial outcomes on breast cancer survivor population.